Kenneth A Howard

List of Publications by Year
in descending order

90 papers	6,232 citations	87888 38 h-index	69250 77 g-index
90 all docs	90 docs citations	90 times ranked	10234 citing authors

#	Article	IF	Citations
1	RNA Interference in Vitro and in Vivo Using a Novel Chitosan/siRNA Nanoparticle System. Molecular Therapy, 2006, 14, 476-484.	8.2	549
2	Albumin-based drug delivery: harnessing nature to cure disease. Molecular and Cellular Therapies, 2016, 4, 3.	0.2	480
3	The influence of polymeric properties on chitosan/siRNA nanoparticle formulation and gene silencing. Biomaterials, 2007, 28, 1280-1288.	11.4	382
4	Importance of Lateral and Steric Stabilization of Polyelectrolyte Gene Delivery Vectors for Extended Systemic Circulation. Molecular Therapy, 2002, 5, 463-472.	8.2	273
5	Chitosan/siRNA Nanoparticleâ€“mediated TNF-Î± Knockdown in Peritoneal Macrophages for Anti-inflammatory Treatment in a Murine Arthritis Model. Molecular Therapy, 2009, 17, 162-168.	8.2	270
6	Comparative analysis of discrete exosome fractions obtained by differential centrifugation. Journal of Extracellular Vesicles, 2014, 3, 25011.	12.2	262
7	Size-Dependent Accumulation of PEGylated Silane-Coated Magnetic Iron Oxide Nanoparticles in Murine Tumors. ACS Nano, 2009, 3, 1947-1951.	14.6	242
8	Cellular Disposal of miR23b by RAB27-Dependent Exosome Release Is Linked to Acquisition of Metastatic Properties. Cancer Research, 2014, 74, 5758-5771.	0.9	237
9	Multifunctional Bismuth Selenide Nanocomposites for Antitumor Thermo-Chemotherapy and Imaging. ACS Nano, 2016, 10, 984-997.	14.6	234
10	Antimicrobial Effect of Chitosan Nanoparticles on Streptococcus mutans Biofilms. Applied and Environmental Microbiology, 2011, 77, 3892-3895.	3.1	183
11	Multimodal Imaging-Guided Antitumor Photothermal Therapy and Drug Delivery Using Bismuth Selenide Spherical Sponge. ACS Nano, 2016, 10, 9646-9658.	14.6	175
12	Decreased Binding to Proteins and Cells of Polymeric Gene Delivery Vectors Surface Modified with a Multivalent Hydrophilic Polymer and Retargeting through Attachment of Transferrin. Journal of Biological Chemistry, 2000, 275, 3793-3802.	3.4	148
13	Quantitative proteomics of fractionated membrane and lumen exosome proteins from isogenic metastatic and nonmetastatic bladder cancer cells reveal differential expression of EMT factors. Proteomics, 2014, 14, 699-712.	2.2	148
14	Polycation-based nanoparticle delivery of RNAi therapeutics: Adverse effects and solutions. Advanced Drug Delivery Reviews, 2012, 64, 1717-1729.	13.7	136
15	Steric Stabilization of poly-l-Lysine/DNA Complexes by the Covalent Attachment of Semitelechelic poly[N-(2-Hydroxypropyl)methacrylamide]. Bioconjugate Chemistry, 2000, 11, 492-501.	3.6	109
16	Pelletâ€free isolation of human and bovine milk extracellular vesicles by sizeâ€exclusion chromatography. Journal of Extracellular Vesicles, 2017, 6, 1294340.	12.2	101
17	Delivery of siRNA from lyophilized polymeric surfaces. Biomaterials, 2008, 29, 506-512.	11.4	100
18	Intracellular bacteria engage a STINGâ€“TBK1â€“MVB12b pathway to enable paracrine cGASâ€“STING signalling. Nature Microbiology, 2019, 4, 701-713.	13.3	100

#	Article	IF	Citations
19	Highly porous PEGylated Bi₂S₃nano-urchins as a versatile platform for in vivo triple-modal imaging, photothermal therapy and drug delivery. Nanoscale, 2016, 8, 16005-16016.	5.6	90
20	Pulmonary Gene Silencing in Transgenic EGFP Mice Using Aerosolised Chitosan/siRNA Nanoparticles. Pharmaceutical Research, 2010, 27, 2520-2527.	3.5	87
21	Tumour exosomes display differential mechanical and complement activation properties dependent on malignant state: implications in endothelial leakiness. Journal of Extracellular Vesicles, 2015, 4, 29685.	12.2	86
22	Spatial Mapping and Quantification of Soft and Hard Protein Coronas at Silver Nanocubes. Nano Letters, 2014, 14, 2086-2093.	9.1	85
23	siRNA Nanoparticle Functionalization of Nanostructured Scaffolds Enables Controlled Multilineage Differentiation of Stem Cells. Molecular Therapy, 2010, 18, 2018-2027.	8.2	81
24	Chitosan/siRNA Nanoparticles Biofunctionalize Nerve Implants and Enable Neurite Outgrowth. Nano Letters, 2010, 10, 3933-3939.	9.1	78
25	Protection and Systemic Translocation of siRNA Following Oral Administration of Chitosan/siRNA Nanoparticles. Molecular Therapy - Nucleic Acids, 2013, 2, e76.	5.1	65
26	Accumulation of magnetic iron oxide nanoparticles coated with variably sized polyethylene glycol in murine tumors. Nanoscale, 2012, 4, 2352.	5.6	61
27	Direct demonstration of a neonatal Fc receptor (FcRn)-driven endosomal sorting pathway for cellular recycling of albumin. Journal of Biological Chemistry, 2017, 292, 13312-13322.	3.4	60
28	Intraperitoneal administration of chitosan/DsiRNA nanoparticles targeting TNFÎ± prevents radiation-induced fibrosis. Radiotherapy and Oncology, 2010, 97, 143-148.	0.6	57
29	Surface functionalisation of PLGA nanoparticles for gene silencing. Biomaterials, 2010, 31, 5671-5677.	11.4	53
30	Direct Force Measurements between siRNA and Chitosan Molecules Using Force Spectroscopy. Biophysical Journal, 2007, 93, 952-959.	0.5	52
31	Nanocarrier Stimuli-Activated Gene Delivery. Small, 2007, 3, 54-57.	10.0	48
32	A hyaluronic acid-based hydrogel enabling CD44-mediated chondrocyte binding and gapmer oligonucleotide release for modulation of gene expression in osteoarthritis. Journal of Controlled Release, 2017, 253, 153-159.	9.9	47
33	Ultraporous interweaving electrospun microfibers from PCLâ€“PEO binary blends and their inflammatory responses. Nanoscale, 2014, 6, 3392.	5.6	45
34	Polycation-based nanoparticle delivery for improved RNA interference therapeutics. Expert Opinion on Biological Therapy, 2007, 7, 1811-1822.	3.1	44
35	Regulation of Gdf5 expression in joint remodelling, repair and osteoarthritis. Scientific Reports, 2020, 10, 157.	3.3	44
36	Intracellular siRNA and precursor miRNA trafficking using bioresponsive copolypeptides. Journal of Gene Medicine, 2008, 10, 81-93.	2.8	43

#	Article	IF	Citations
37	Bioresponsive hyperbranched polymers for siRNA and miRNA delivery. Journal of Drug Targeting, 2010, 18, 812-820.	4.4	43
38	Humanâ€Serumâ€Albuminâ€Coated Prussian Blue Nanoparticles as pHâ€Thermotriggered Drugâ€Delivery Vehicles for Cancer Thermochemotherapy. Particle and Particle Systems Characterization, 2016, 33, 53-62.	2.3	42
39	Albumin-based drug designs for pharmacokinetic modulation. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 783-795.	3.3	42
40	Fatty Acid-Modified Gapmer Antisense Oligonucleotide and Serum Albumin Constructs for Pharmacokinetic Modulation. Molecular Therapy, 2017, 25, 1710-1717.	8.2	39
41	Generation of a double transgenic humanized neonatal Fc receptor (FcRn)/albumin mouse to study the pharmacokinetics of albumin-linked drugs. Journal of Controlled Release, 2016, 223, 22-30.	9.9	35
42	Fibrin-hyaluronic acid hydrogel-based delivery of antisense oligonucleotides for ADAMTS5 inhibition in co-delivered and resident joint cells in osteoarthritis. Journal of Controlled Release, 2019, 294, 247-258.	9.9	34
43	Protection against bubonic and pneumonic plague with a single dose microencapsulated sub-unit vaccine. Vaccine, 2006, 24, 4433-4439.	3.8	33
44	Synthesis of clickâ€reactive HPMA copolymers using RAFT polymerization for drug delivery applications. Journal of Polymer Science Part A, 2013, 51, 5091-5099.	2.3	31
45	An albumin-mediated cholesterol design-based strategy for tuning siRNA pharmacokinetics and gene silencing. Journal of Controlled Release, 2016, 232, 143-151.	9.9	31
46	Cellular recycling-driven in vivo half-life extension using recombinant albumin fusions tuned for neonatal Fc receptor (FcRn) engagement. Journal of Controlled Release, 2018, 287, 132-141.	9.9	29
47	FcRn overexpression in human cancer drives albumin recycling and cell growth; a mechanistic basis for exploitation in targeted albumin-drug designs. Journal of Controlled Release, 2020, 322, 53-63.	9.9	29
48	Programmable half-life and anti-tumour effects of bispecific T-cell engager-albumin fusions with tuned FcRn affinity. Communications Biology, 2021, 4, 310.	4.4	29
49	Hyaluronic Acid Molecular Weight-Dependent Modulation of Mucin Nanostructure for Potential Mucosal Therapeutic Applications. Molecular Pharmaceutics, 2017, 14, 2359-2367.	4.6	28
50	Physicochemical and biological characterisation of an antisense oligonucleotide targeted against the bcl-2 mRNA complexed with cationicâ€hydrophilic copolymers. European Journal of Pharmaceutical Sciences, 2000, 10, 169-177.	4.0	26
51	Chitosan-Based Nanoparticles for Mucosal Delivery of RNAi Therapeutics. Advances in Genetics, 2014, 88, 325-352.	1.8	26
52	Targeting the IL-6â€Yapâ€Snail signalling axis in synovial fibroblasts ameliorates inflammatory arthritis. Annals of the Rheumatic Diseases, 2022, 81, 214-224.	0.9	26
53	The Immunomodulatory Drug Glatiramer Acetate is Also an Effective Antimicrobial Agent that Kills Gram-negative Bacteria. Scientific Reports, 2017, 7, 15653.	3.3	25
54	An Albumin-Oligonucleotide Assembly for Potential Combinatorial Drug Delivery and Half-Life Extension Applications. Molecular Therapy - Nucleic Acids, 2017, 9, 284-293.	5.1	23

#	Article	IF	Citations
55	Size-Selective Phagocytic Clearance of Fibrillar Î±-Synuclein through Conformational Activation of Complement Receptor 4. Journal of Immunology, 2020, 204, 1345-1361.	0.8	23
56	Peritoneal macrophages mediated delivery of chitosan/siRNA nanoparticle to the lesion site in a murine radiation-induced fibrosis model. Acta OncolÃ³gica, 2013, 52, 1730-1738.	1.8	22
57	Polycation-based nanoparticles for RNAi-mediated cancer treatment. Cancer Letters, 2014, 352, 66-80.	7.2	22
58	Site-selective conjugation of an anticoagulant aptamer to recombinant albumins and maintenance of neonatal Fc receptor binding. Nanotechnology, 2017, 28, 204004.	2.6	20
59	Albumin-based drug delivery using cysteine 34 chemical conjugates â€“ important considerations and requirements. Therapeutic Delivery, 2017, 8, 511-519.	2.2	20
60	Independent Validation of a Diagnostic Noninvasive 3-MicroRNA Ratio Model (uCaP) for Prostate Cancer in Cell-Free Urine. Clinical Chemistry, 2019, 65, 540-548.	3.2	20
61	Cell type and transfection reagent-dependent effects on viability, cell content, cell cycle and inflammation of RNAi in human primary mesenchymal cells. European Journal of Pharmaceutical Sciences, 2014, 53, 35-44.	4.0	19
62	Albumin: the next-generation delivery technology. Therapeutic Delivery, 2015, 6, 265-268.	2.2	19
63	Tunable CD44-Specific Cellular Retargeting with Hyaluronic Acid Nanoshells. Pharmaceutical Research, 2015, 32, 1462-1474.	3.5	18
64	Neonatal Fc Receptor Binding Tolerance toward the Covalent Conjugation of Payloads to Cysteine 34 of Human Albumin Variants. Molecular Pharmaceutics, 2016, 13, 677-682.	4.6	18
65	Roadmap on nanomedicine. Nanotechnology, 2021, 32, 012001.	2.6	17
66	Formulation of a microparticle carrier for oral polyplex-based DNA vaccines. Journal of Financial Economics, 2004, 1674, 149-57.	9.0	15
67	The random co-polymer glatiramer acetate rapidly kills primary human leukocytes through sialic-acid-dependent cell membrane damage. Biochimica Et Biophysica Acta - Biomembranes, 2017, 1859, 425-437.	2.6	15
68	A new class of recombinant human albumin with multiple surface thiols exhibits stable conjugation and enhanced FcRn binding and blood circulation. Journal of Biological Chemistry, 2019, 294, 3735-3743.	3.4	15
69	FcRn expression in cancer: Mechanistic basis and therapeutic opportunities. Journal of Controlled Release, 2021, 337, 248-257.	9.9	15
70	Optimised approach to albuminâ€“drug conjugates using monobromomaleimide-C-2 linkers. Organic and Biomolecular Chemistry, 2019, 17, 7870-7873.	2.8	14
71	The application of RNAi-based treatments for inflammatory bowel disease. Drug Delivery and Translational Research, 2014, 4, 4-18.	5.8	12
72	Oligonucleotide Delivery to the Lung: Waiting to Inhale. Molecular Therapy - Nucleic Acids, 2012, 1, e1.	5.1	11

#	Article	IF	Citations
73	Mucus barrier-triggered disassembly of siRNA nanocarriers. Nanoscale, 2014, 6, 12547-12554.	5.6	11
74	Providing the full picture: a mandate for standardizing nanoparticle-based drug delivery. Nanomedicine, 2013, 8, 1031-1033.	3.3	10
75	Surface Analysis of PEGylated Nano-Shields on Nanoparticles Installed by Hydrophobic Anchors. Pharmaceutical Research, 2013, 30, 1758-1767.	3.5	10
76	Mucin-mediated nanocarrier disassembly for triggered uptake of oligonucleotides as a delivery strategy for the potential treatment of mucosal tumours. Nanoscale, 2016, 8, 12599-12607.	5.6	10
77	Targeting Biological Barriers: Turning a Wall into a Therapeutic Springboard. Molecular Therapy, 2018, 26, 933-934.	8.2	7
78	Functionalized Acyclic (<scp>l</scp>)â€Threoninol Nucleic Acid Fourâ€Way Junction with High Stability In Vitro and In Vivo. Angewandte Chemie - International Edition, 2022, 61, .	13.8	7
79	Clinical translation of RNAi-based treatments for respiratory diseases. Drug Delivery and Translational Research, 2013, 3, 84-99.	5.8	6
80	Albumin Biomolecular Drug Designs Stabilized through Improved Thiol Conjugation and a Modular Locked Nucleic Acid Functionalized Assembly. Bioconjugate Chemistry, 2022, 33, 333-342.	3.6	6
81	Extended blood circulation and joint accumulation of a p(HPMA-co-AzMA)-based nanoconjugate in a murine model of rheumatoid arthritis. Molecular and Cellular Therapies, 2014, 2, 29.	0.2	5
82	Nanomedicine: Working Towards Defining the Field. Advances in Delivery Science and Technology, 2016, , 1-12.	0.4	5
83	Palmitoylated phosphodiester gapmer designs with albumin binding capacity and maintained in vitro gene silencing activity. Journal of Gene Medicine, 2018, 20, e3025.	2.8	4
84	Visualization of thermally activated nanocarriers usingin situatomic force microscopy. Nanotechnology, 2007, 18, 185501.	2.6	3
85	Mucosal Delivery of RNAi Therapeutics. Advances in Delivery Science and Technology, 2013, , 97-125.	0.4	2
86	RNA interference-based therapeutics and diagnostics. Drug Delivery and Translational Research, 2014, 4, 1-2.	5.8	2
87	Chipâ€Free Microscaleâ€Incubatorâ€Based Synthesis of Chitosanâ€Based Gene Silencing Nanoparticles. Particle and Particle Systems Characterization, 2016, 33, 279-285.	2.3	1
88	Bioengineered solutions to improve cancer immunotherapies. Therapeutic Delivery, 2021, 12, 339-341.	2.2	1
89	Albumin-Binding Fatty Acidâ€“Modified Gapmer Antisense Oligonucleotides for Modulation of Pharmacokinetics. Methods in Molecular Biology, 2020, 2176, 163-174.	0.9	1
90	Functionalized Acyclic (L)â€Threoninol Nucleic Acid Four Way Junction with High Stability in Vitro and in Vivo. Angewandte Chemie, 0, , .	2.0	0